Aravive (ARAV) Competitors

Aravive (NASDAQ:ARAV) and Minerva Neurosciences (NASDAQ:NERV) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, community ranking, risk, media sentiment, profitability, dividends, earnings and analyst recommendations.

Which has higher valuation and earnings, ARAV or NERV?

Minerva Neurosciences has lower revenue, but higher earnings than Aravive.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aravive	$6.99M	0.42	-$76.32M	N/A	N/A
Minerva Neurosciences	N/A	N/A	-$30M	$0.82	1.77

Does the MarketBeat Community favor ARAV or NERV?

Minerva Neurosciences received 243 more outperform votes than Aravive when rated by MarketBeat users. However, 62.28% of users gave Aravive an outperform vote while only 55.52% of users gave Minerva Neurosciences an outperform vote.

Company	Underperform	Outperform
Aravive	Outperform Votes 104 62.28%	Underperform Votes 63 37.72%
Minerva Neurosciences	Outperform Votes 347 55.52%	Underperform Votes 278 44.48%

Do insiders & institutionals have more ownership in ARAV or NERV?

35.8% of Aravive shares are held by institutional investors. Comparatively, 34.6% of Minerva Neurosciences shares are held by institutional investors. 60.4% of Aravive shares are held by company insiders. Comparatively, 8.6% of Minerva Neurosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Is ARAV or NERV more profitable?

Company	Net Margins	Return on Equity	Return on Assets
Aravive	N/A	N/A	N/A
Minerva Neurosciences	N/A	N/A	-6.74%

Does the media favor ARAV or NERV?

In the previous week, Minerva Neurosciences had 1 more articles in the media than Aravive. MarketBeat recorded 1 mentions for Minerva Neurosciences and 0 mentions for Aravive. Aravive's average media sentiment score of 0.00 equaled Minerva Neurosciences'average media sentiment score.

Company	Overall Sentiment
Aravive	Neutral
Minerva Neurosciences	Neutral

Do analysts prefer ARAV or NERV?

Minerva Neurosciences has a consensus target price of $5.00, indicating a potential upside of 244.83%. Given Minerva Neurosciences' stronger consensus rating and higher probable upside, analysts clearly believe Minerva Neurosciences is more favorable than Aravive.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aravive	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Minerva Neurosciences	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Which has more volatility and risk, ARAV or NERV?

Aravive has a beta of 2.19, meaning that its share price is 119% more volatile than the S&P 500. Comparatively, Minerva Neurosciences has a beta of -0.5, meaning that its share price is 150% less volatile than the S&P 500.

Summary

Aravive beats Minerva Neurosciences on 6 of the 11 factors compared between the two stocks.